Loading
Life sciences · Journal article
Small · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Deep and spatially uniform drug delivery remains a major challenge in nanomedicine for solid tumor therapy. During delivery, nanoparticles must sequentially traverse multiple biological barriers, from systemic circulation and tumor accumulation to vascular extravasation, basement-membrane crossing, interstitial penetration, and cellular internalization. In this review, we distinguish the sheet-like perivascular basement membrane from the fibrillar, hydrated interstitial extracellular matrix and discuss how intertumoral, intratumoral, and stage-specific heterogeneity alters the dominant transport barriers across different tumor contexts. We then summarize three complementary strategies for engineering nanoparticles to improve deep tumor penetration: 1) Nanocarrier design, which tunes particle shape, size, surface charge, mechanical stiffness, and ligand presentation to balance cellular interactions and interstitial mobility; 2) Vascular and Stromal Modulation, which alleviates transport barriers through vascular normalization, transient basement-membrane modulation, controlled extracellular-matrix remodeling, and regulation of matrix production by cancer-associated fibroblasts; 3) Active and Assisted Transport, which promotes trans-barrier delivery through transcytosis, self-propelled nanomotors, and externally applied physical energy. We discuss the associated challenges and optimization strategies, particularly those related to spatial penetration, tumor accumulation, model-dependent efficacy, and safety. Finally, we highlight the translational limitations and future opportunities of tumor-penetrating nanomedicines from a clinical perspective.